Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator-initiated Phase 1/2 clinical trial for metastatic colorectal cancer (CRC), hepatocellular carcinoma (HCC), and cholangiocarcinoma in collaboration with VCU Massey Comprehensive Cancer Center

Next Previous
Trial Profile

An investigator-initiated Phase 1/2 clinical trial for metastatic colorectal cancer (CRC), hepatocellular carcinoma (HCC), and cholangiocarcinoma in collaboration with VCU Massey Comprehensive Cancer Center

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icomidocholic acid (Primary) ; Metformin (Primary) ; Regorafenib (Primary)
  • Indications Carcinoma; Cholangiocarcinoma; Colorectal cancer; Liver cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 15 Dec 2025 New trial record
  • 08 Dec 2025 According to the Galmed Pharmaceuticals media release, once a recommended Phase 2 dose is found in this study, Galmed plans to add a dose expansion cohort that will include Metformin and will evaluate the 3-drug combination efficacy.
  • 08 Dec 2025 According to the Galmed Pharmaceuticals media release, the translational findings being presented at HEP-DART 2025 Meeting, provide the scientific and translational rationale for the initiation of a Phase 1/2 clinical trial of the combination of standard of care regorafenib with the SCD1 inhibitor Aramchol in HCC and other GI cancers.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top